Apellis Pharmaceuticals, INC Form 4 insider transactions

James George Chopas, VP/Chief Accounting Officer of Apellis Pharmaceuticals, sold 1,096 shares of common stock on January 22, 2025, to cover tax withholding obligations.

David O. Watson, General Counsel of Apellis Pharmaceuticals, reported the sale of 2,201 shares and the acquisition of 42,762 shares through a restricted stock unit award.

Adam J. Townsend, Chief Commercial Officer of Apellis Pharmaceuticals, sold 2,201 shares of common stock to cover tax withholding obligations related to restricted stock units.

Apellis Pharmaceuticals' Chief Financial Officer, Timothy Sullivan, reported the sale of 1,730 shares and the acquisition of 45,929 restricted stock units.

Nur Nicholson, Chief Technical Officer of Apellis Pharmaceuticals, reports selling shares to cover tax withholding and receiving a restricted stock unit (RSU) award.

Karen Lewis, Chief People Officer of Apellis Pharmaceuticals, reports selling shares to cover tax withholding and receiving a restricted stock unit (RSU) award.

CEO Cedric Francois reports the sale of shares to cover tax withholding and the grant of restricted stock units.

Apellis Pharmaceuticals' Chief Scientific Officer, Pascal Deschatelets, sold shares to cover tax obligations and received a restricted stock unit award.

Mark Jeffrey DeLong, Chief Business & Strategy Officer at Apellis Pharmaceuticals, sold shares to cover tax obligations and received a new restricted stock unit award.

Apellis Pharmaceuticals' VP/Chief Accounting Officer, James Chopas, reports the sale of 715 shares and the acquisition of 12,591 restricted stock units.

Caroline Baumal, Chief Medical Officer of Apellis Pharmaceuticals, reports the sale of shares to cover tax withholding and the acquisition of restricted stock units.

David Watson, General Counsel of Apellis Pharmaceuticals, reports the sale of 4,965 shares of common stock to cover tax withholding related to restricted stock units.

Adam J. Townsend, Chief Commercial Officer of Apellis Pharmaceuticals, sold 2,685 shares of common stock to cover tax withholding on restricted stock units.

Apellis Pharmaceuticals' Chief Financial Officer, Timothy Eugene Sullivan, sold 2,170 shares of common stock to cover tax obligations related to restricted stock units.

Nur Nicholson, Chief Technical Officer of Apellis Pharmaceuticals, sold 2,632 shares of common stock on January 13, 2025, to cover tax withholding related to released Restricted Stock Units.

Karen Lewis, Chief People Officer of Apellis Pharmaceuticals, sold 1,599 shares of common stock on January 13, 2025, to cover tax obligations related to released Restricted Stock Units.

Apellis Pharmaceuticals CEO, Cedric Francois, sold 6,247 shares of common stock to cover tax obligations related to released Restricted Stock Units.

Apellis Pharmaceuticals' Chief Development Officer, Jeffrey Eisele, sold 264 shares of common stock to cover tax withholding obligations related to restricted stock units.

Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals, sold 2,288 shares of common stock on January 13, 2025, to cover tax obligations related to released Restricted Stock Units.

Mark Jeffrey DeLong, Chief Business & Strategy Officer of Apellis Pharmaceuticals, sold 1,599 shares of common stock on January 13, 2025, to cover tax withholding on restricted stock units.

James Chopas, VP and Chief Accounting Officer of Apellis Pharmaceuticals, sold 783 shares of common stock to cover tax withholding obligations.

Director Keli Walbert of Apellis Pharmaceuticals reported the acquisition of restricted stock units and stock options on January 8, 2025.

Caroline Baumal, Chief Medical Officer of Apellis Pharmaceuticals, sold 2,816 shares of common stock on January 6, 2025, to cover tax withholding obligations.

Director Stephanie O'Brien reports acquisition of restricted stock units and stock options in Apellis Pharmaceuticals on January 1, 2025.

Director Alec Machiels of Apellis Pharmaceuticals reports acquisition of restricted stock units and stock options, along with indirect holdings through various entities.

Director Paul Fonteyne reports acquisition of restricted stock units and stock options in Apellis Pharmaceuticals on January 1, 2025.

Director A. Sinclair Dunlop reports acquisition of restricted stock units and stock options in Apellis Pharmaceuticals, along with indirect ownership through Epidarex.

Director Gerald Chan reports acquisition of common stock and stock options in Apellis Pharmaceuticals.

Chief Financial Officer of Apellis Pharmaceuticals, Timothy Sullivan, reports exercising stock options and acquiring common stock on December 31, 2024.

Jeffrey Eisele, Chief Development Officer of Apellis Pharmaceuticals, sold 63 shares of common stock on December 23, 2024, to cover tax withholding obligations related to restricted stock units.